Celldex Therapeutics (CLDX) has disclosed a new risk, in the Regulation category.
Celldex Therapeutics faces significant business risk due to the extensive and unpredictable nature of the FDA’s premarket review process for their drug product candidates. The FDA’s considerable discretion can lead to delays, limitations, or outright denials in product approval, which inherently jeopardizes Celldex’s potential to generate operating revenues. With no marketing applications currently submitted, the uncertainty in the approval timeline, compounded by potential additional requirements or changes in FDA policies, poses a substantial threat to the company’s financial and operational outlook.
Overall, Wall Street has a Strong Buy consensus rating on CLDX stock based on 5 Buys and 1 Hold.
To learn more about Celldex Therapeutics’ risk factors, click here.
